Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques (Q41553098)

3 October 2017

title

Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques (English)

1 reference

3 October 2017

Kathryn Patton

1

1 reference

3 October 2017

Shahin Aslam

2

1 reference

3 October 2017

Cindy Shambaugh

3

1 reference

3 October 2017

Rui Lin

4

1 reference

3 October 2017

Darren Heeke

5

1 reference

3 October 2017

Chris Frantz

6

1 reference

3 October 2017

Fengrong Zuo

7

1 reference

3 October 2017

Mark T Esser

8

1 reference

3 October 2017

Xavier Paliard

9

1 reference

3 October 2017

Stacie L Lambert

10

1 reference

3 October 2017

language of work or name

English

0 references

publication date

20 July 2015

1 reference

3 October 2017

1 reference

3 October 2017

volume

33

1 reference

3 October 2017

issue

36

1 reference

3 October 2017

page(s)

4472-4478

1 reference

Pathogenesis of respiratory syncytial virus infection

3 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Respiratory syncytial virus infection in elderly and high-risk adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Influenza- and RSV-associated hospitalizations among adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Respiratory syncytial virus vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Respiratory syncytial virus: current progress in vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Translational sciences approach to RSV vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Risk factors for severe respiratory syncytial virus infection in elderly persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Experimental infection of humans with A2 respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Immunity to and frequency of reinfection with respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Respiratory Syncytial Virus Infections within Families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Macaque models of human infectious disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

B lymphocytes: how they develop and function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Adjuvant solution for pandemic influenza vaccine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.07.025

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2015.07.025

1 reference

3 October 2017

1 reference